Xeris Biopharma Holdings, Inc. (XERS) FY2025 10-K Annual Report
Xeris Biopharma Holdings, Inc. (XERS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 2, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Xeris Biopharma Holdings, Inc. FY2025 10-K Analysis
Business Overview
- • Commercial-stage biopharma focused on therapies for chronic endocrine and neurological diseases in the U.S., with three commercial products: Recorlev, Gvoke, Keveyis
- • Phase 3-ready XP-8121: once-weekly subcutaneous levothyroxine injection leveraging proprietary XeriSol tech, planned Phase 3 start in 2026
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in the provided MD&A section
- • Financing cash inflow $11.4M in 2025 vs $36.2M in 2024; driven by $20.7M stock awards and $10.9M stock repurchases
Risk Factors
- • Risk of SBA PPP Loan audit/enforcement under CARES Act until May 2026, potentially diverting management resources and incurring costs
- • Geopolitical and macroeconomic risks impairing capital access due to inflation, interest rates, bank failures, and financial market volatility
Xeris Biopharma Holdings, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$292M
▲ +43.7% YoY
Net Income
$554,000
▲ +101.0% YoY
Operating Margin
8.5%
▲ +2510bp YoY
Net Margin
0.2%
▲ +2719bp YoY
ROE
4.0%
▼ -18112bp YoY
Total Assets
$384M
▲ +18.7% YoY
EPS (Diluted)
$0.00
▲ +100.0% YoY
Operating Cash Flow
$29M
▲ +177.4% YoY
Source: XBRL data from Xeris Biopharma Holdings, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Xeris Biopharma Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.